News
FDA advisors split on Biogen’s ALS therapy
Biogen’s chances of getting an FDA approval for its tofersen drug candidate for amyotrophic lateral sclerosis (ALS) patients who have mutations in the SOD1 gene have been
Friday 31 March 2023
